Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT06093815
Other study ID # M900311010
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date September 8, 2023
Est. completion date April 2025

Study information

Verified date May 2024
Source Merz North America, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is to identify and assess in vivo tissue responses after injection with various biostimulatory products at various timepoints. The study will also provide tissue specimens which will be used in a subsequent study. Safety endpoint: incidence of adverse events.


Description:

The objective of this study is to identify and assess tissue responses after injection with various biostimulatory products that are already used in the market and have CE approval. The study will assess in vivo tissue responses and provide tissue specimens which will be used in a subsequent study, under a separate protocol. Assessments under this protocol will include ultrasound of in vivo tissue. Safety endpoint: incidence of adverse events.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 20
Est. completion date April 2025
Est. primary completion date May 1, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 22 Years to 65 Years
Eligibility Inclusion Criteria: 1. Healthy male & females; 22 to 65 years of age. 2. Voluntary participation 3. Ability to comprehend and provide informed consent. 4. Participants agree NOT to use any topical agents or products that will induce skin peeling or change the appearance of the skin in the treatment area, during the study period. 5. Participants agree NOT to undergo any aesthetic treatments that influence the appearance of the skin in the treatment area during the study period. 6. Participants agree NOT to undergo any surgical treatments in the treatment area during the study period. 7. Participants agree NOT to take part in another clinical study or undergo other treatments during the study period. Exclusion Criteria: 1. Any previous surgery in the abdominal area. 2. Any previous treatment in the abdominal area. 3. Planning to receive treatment of any kind in the abdominal area. 4. Acute inflammatory process and/or infection at the injection site. 5. Treatment of skin area with dermatosis. 6. Eczema, exanthema or open wounds. 7. Previous application of over the counter or prescription, oral or topical, anti-wrinkle or skin enhancer products on the abdominal skin within the past 3 months unless allowed by the study and is continued throughout the study. 8. Any contraindication to treatment with biostimulatory products based on the product's IFU. 9. Previous pregnancy or intending to become pregnant during study participation. 10. Known hypersensitivity to biostimulatory products or any of their formulation ingredients. 11. Allergic reaction to topical and local anesthetics. 12. Currently using anticoagulant therapy. 13. Haemophilia / bleeding disorder. 14. Chemotherapy, radiotherapy or high doses of corticosteroids. 15. Systemic infection (e.g., hepatitis). 16. Uncontrolled diabetes mellitus. 17. Any medical condition that may put the participant at increased risk with exposure to biostimulatory products. 18. Any medication that might modulate the immune response. 19. Any other illness or condition that, in the opinion of the investigator, would mean that study participation was not in the best interest of the prospective participant. 20. Is a female of childbearing potential and not using medically effective birth control or is pregnant or lactating. 21. Any serious disease or disorder (medical or psychiatric) that could, in the opinion of the investigator, interfere with the safe completion of treatment according to this protocol or with study. 22. Injection of local anesthesia into the flap during abdominoplasty surgery.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Injection
A pre specified amount will be injected in tissue at selected timepoints

Locations

Country Name City State
Spain Ocean Clinic - Av. Ramon y Cajal 7, 29601 Marbella

Sponsors (1)

Lead Sponsor Collaborator
Merz North America, Inc.

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Other Safety Assessment Adverse event reporting through study completion, an average of 6 months
Primary Ultrasound Analyses Ultrasound of injection site tissue analyses (dermal thickness (mm), elastosis (mm) and microvascular formation) by PI at various timepoints 6 months, 3 months and 2 weeks prior to surgery timepoint(s)
See also
  Status Clinical Trial Phase
Completed NCT05007041 - Simultaneous RZV and aIIV4 Vaccination Phase 4
Completed NCT05157230 - Evaluation of Deltoid Exercises on Injection Site Pain After (BNT162b2) COVID - 19 Vaccination N/A
Completed NCT05028361 - Simultaneous mRNA COVID-19 and IIV4 Vaccination Study Phase 4
Completed NCT03645369 - Effectiveness of Mechano-Analgesia and Cold Application on Ecchymosis, Pain and Satisfaction at Subcutaneous Heparin Injection N/A
Completed NCT03841396 - A Study Comparing the Local Tolerability of Two Subcutaneous Heparins in Healthy Volunteers. Phase 4
Recruiting NCT04962152 - Naldebain and Video-assisted Thoracoscopic Surgery Phase 4
Completed NCT03183908 - FLUAD® vs. Fluzone® High-Dose Study Phase 4
Recruiting NCT05221333 - Sorrel 25R Injector - Sorrel Clinical Study Protocol N/A
Completed NCT05157191 - Safety of Pediatric COVID-19 Vaccination